Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Gliosarcoma 1Glioblastoma 1

Interventions

Cisplatin 18pembrolizumab 12Paclitaxel 9Carboplatin 9Radiotherapy 5Gemcitabine 4Fluorodeoxyglucose F18 4Colposcopy 4Brachytherapy 4fludarabine 3durvalumab 3Surveys and Questionnaires 3Radiation 3Flow Cytometry 3Cyclophosphamide 3Biopsy 3Bevacizumab 3toripalimab 2fludarabine phosphate 2atezolizumab 2aldesleukin 2adavosertib 2Zoledronic Acid 2Topotecan 2Nivolumab 2Neoadjuvant Therapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Interleukin-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uterine Cervical Neoplasms × Automobiles × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡